Table 1. Summary of HDACIs in cervical cancer recently.

Name	Type	Property	Disease or cell	Reference
2-Aminobenzamides compound M122	Especially inhibit HDAC1 HDAC2	High potency and selectivity	HeLa, etc.	[21]
2-Oxo-1,3-thiazolidine derivatives	Class II HDACIs	Good bioactivities, oral bioavailability	Cervical cancer	[22]
TSA	Except for class III HDACs	Acetylated HIF-1α at lysine 674	HeLa cells	[50,51]
Vorinostat (SAHA)	Pan-HDAC inhibitor	Reduce E6 and E7 activity	HPV infections	[52,53]
Oxamflatin	HDAC inhibitor	Induces E-cadherin Expression	HeLa cells	[54]
Valproic acid (VPA)	HDAC inhibitor	Re-expression of E-cadherin	HeLa and TC1 cell lines	[55]
OH-VPA	HDAC inhibitor	Antioxidant	HeLa cells	[56]
Genistein	HDAC families	Time-dependent	HeLa cells	[57]
Caffeic acid	HDAC inhibitor	Induction of apoptosis	Colon and cervical cancer cells	[58]
Mocetinostat and entinostat	Class I HDACIs	Pan-gynecologic cancer inhibitors	Ovarian, cervical cells, etc.	[59]
Scriptaid (SCR)	HDAC-8 inhibitor	Inhibit HDAC-8 effectively than TSA	HeLa cells, etc.	[60]
Isatin-based compounds	HDACIs	Inhibit proliferation	HeLa cells	[61]